|
1
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luqmani YA: Mechanisms of drug resistance
in cancer chemotherapy. Med Princ Pract. 14:(Suppl 1). 35–48. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zahreddine H and Borden KL: Mechanisms and
insights into drug resistance in cancer. Front Pharmacol. 4:282013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xue X and Liang XJ: Overcoming drug
efflux-based multidrug resistance in cancer with nanotechnology.
Chin J Cancer. 31:100–109. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Amin ML: P-glycoprotein inhibition for
optimal drug delivery. Drug Target Insights. 7:27–34. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JH, Zhou HY, Cho SY, Kim YS, Lee YS
and Jeong CS: Anti-inflammatory mechanisms of apigenin: inhibition
of cyclooxygenase-2 expression, adhesion of monocytes to human
umbilical vein endothelial cells, and expression of cellular
adhesion molecules. Arch Pharm Res. 30:1318–1327. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Romanová D, Vachálková A, Cipák L, Ovesná
Z and Rauko P: Study of antioxidant effect of apigenin, luteolin
and quercetin by DNA protective method. Neoplasma. 48:104–107.
2001.PubMed/NCBI
|
|
8
|
Moon DO, Kim MO, Choi YH, Lee HG, Kim ND
and Kim GY: Gossypol suppresses telomerase activity in human
leukemia cells via regulating hTERT. FEBS Lett. 582:3367–3373.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakazawa T, Yasuda T, Ueda J and Ohsawa K:
Antidepressant-like effects of apigenin and
2,4,5-trimethoxycinnamic acid from Perilla frutescens in the forced
swimming test. Biol Pharm Bull. 26:474–480. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shukla S and Gupta S: Apigenin: A
promising molecule for cancer prevention. Pharm Res. 27:962–978.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heederik D, Kromhout H, Burema J,
Biersteker K and Kromhout D: Occupational exposure and 25-year
incidence rate of non-specific lung disease: The Zutphen Study. Int
J Epidemiol. 19:945–952. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Knekt P, Järvinen R, Seppänen R,
Hellövaara M, Teppo L, Pukkala E and Aromaa A: Dietary flavonoids
and the risk of lung cancer and other malignant neoplasms. Am J
Epidemiol. 146:223–230. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hertog MG, Feskens EJ, Hollman PC, Katan
MB and Kromhout D: Dietary flavonoids and cancer risk in the
Zutphen Elderly Study. Nutr Cancer. 22:175–184. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rossi M, Negri E, Lagiou P, Talamini R,
Dal Maso L, Montella M, Franceschi S and La Vecchia C: Flavonoids
and ovarian cancer risk: A case-control study in Italy. Int J
Cancer. 123:895–898. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bosetti C, Spertini L, Parpinel M,
Gnagnarella P, Lagiou P, Negri E, Franceschi S, Montella M,
Peterson J, Dwyer J, et al: Flavonoids and breast cancer risk in
Italy. Cancer Epidemiol Biomarkers Prev. 14:805–808. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shukla S, Bhaskaran N, Babcook MA, Fu P,
Maclennan GT and Gupta S: Apigenin inhibits prostate cancer
progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
Carcinogenesis. 35:452–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Budhraja A, Gao N, Zhang Z, Son YO, Cheng
S, Wang X, Ding S, Hitron A, Chen G, Luo J, et al: Apigenin induces
apoptosis in human leukemia cells and exhibits anti-leukemic
activity in vivo. Mol Cancer Ther. 11:132–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu LZ, Fang J, Zhou Q, Hu X, Shi X and
Jiang BH: Apigenin inhibits expression of vascular endothelial
growth factor and angiogenesis in human lung cancer cells:
Implication of chemoprevention of lung cancer. Mol Pharmacol.
68:635–643. 2005.PubMed/NCBI
|
|
19
|
Seo HS, Ju JH, Jang K and Shin I:
Induction of apoptotic cell death by phytoestrogens by
up-regulating the levels of phospho-p53 and p21 in normal and
malignant estrogen receptor α-negative breast cells. Nutr Res.
31:139–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu HF, Chie YJ, Yang MS, Lee CS, Fu JJ,
Yang JS, Tan TW, Wu SH, Ma YS, Ip SW, et al: Apigenin induces
caspase-dependent apoptosis in human lung cancer A549 cells through
Bax- and Bcl-2-triggered mitochondrial pathway. Int J Oncol.
36:1477–1484. 2010.PubMed/NCBI
|
|
21
|
Wang W, Heideman L, Chung CS, Pelling JC,
Koehler KJ and Birt DF: Cell-cycle arrest at G2/M and growth
inhibition by apigenin in human colon carcinoma cell lines. Mol
Carcinog. 28:102–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Turktekin M, Konac E, Onen HI, Alp E,
Yilmaz A and Menevse S: Evaluation of the effects of the flavonoid
apigenin on apoptotic pathway gene expression on the colon cancer
cell line (HT29). J Med Food. 14:1107–1117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gupta S, Afaq F and Mukhtar H: Involvement
of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle
arrest and apoptosis by apigenin in human prostate carcinoma cells.
Oncogene. 21:3727–3738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ruela-de-Sousa RR, Fuhler GM, Blom N,
Ferreira CV, Aoyama H and Peppelenbosch MP: Cytotoxicity of
apigenin on leukemia cell lines: Implications for prevention and
therapy. Cell Death Dis. 1:e192010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ujiki MB, Ding XZ, Salabat MR, Bentrem DJ,
Golkar L, Milam B, Talamonti MS, Bell RH Jr, Iwamura T and Adrian
TE: Apigenin inhibits pancreatic cancer cell proliferation through
G2/M cell cycle arrest. Mol Cancer. 5:762006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
27
|
Zhang X, Xiao W, Wang L, Tian Z and Zhang
J: Deactivation of signal transducer and activator of transcription
3 reverses chemotherapeutics resistance of leukemia cells via
down-regulating P-gp. PLoS One. 6:e209652011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jänicke RU: MCF-7 breast carcinoma cells
do not express caspase-3. Breast Cancer Res Treat. 117:219–221.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Long X, Fan M, Bigsby RM and Nephew KP:
Apigenin inhibits antiestrogen-resistant breast cancer cell growth
through estrogen receptor-alpha-dependent and estrogen
receptor-alpha-independent mechanisms. Mol Cancer Ther.
7:2096–2108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saeed M, Kadioglu O, Khalid H, Sugimoto Y
and Efferth T: Activity of the dietary flavonoid, apigenin, against
multidrug-resistant tumor cells as determined by pharmacogenomics
and molecular docking. J Nutr Biochem. 26:44–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de la Iglesia N, Konopka G, Puram SV, Chan
JA, Bachoo RM, You MJ, Levy DE, Depinho RA and Bonni A:
Identification of a PTEN-regulated STAT3 brain tumor suppressor
pathway. Genes Dev. 22:449–462. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lewis HD, Winter A, Murphy TF, Tripathi S,
Pandey VN and Barton BE: STAT3 inhibition in prostate and
pancreatic cancer lines by STAT3 binding sequence oligonucleotides:
Differential activity between 5′ and 3′ ends. Mol Cancer Ther.
7:1543–1550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kortylewski M, Jove R and Yu H: Targeting
STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev.
24:315–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Niu G, Bowman T, Huang M, Shivers S,
Reintgen D, Daud A, Chang A, Kraker A, Jove R and Yu H: Roles of
activated Src and Stat3 signaling in melanoma tumor cell growth.
Oncogene. 21:7001–7010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie TX, Huang FJ, Aldape KD, Kang SH, Liu
M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3
in human melanoma promotes brain metastasis. Cancer Res.
66:3188–3196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sellers LA, Feniuk W, Humphrey PP and
Lauder H: Activated G protein-coupled receptor induces tyrosine
phosphorylation of STAT3 and agonist-selective serine
phosphorylation via sustained stimulation of mitogen-activated
protein kinase. Resultant effects on cell proliferation. J Biol
Chem. 274:16423–16430. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Turkson J, Carter-Su C, Smithgall
T, Levitzki A, Kraker A, Krolewski JJ, Medveczky P and Jove R:
Activation of Stat3 in v-Src-transformed fibroblasts requires
cooperation of Jak1 kinase activity. J Biol Chem. 275:24935–24944.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kotha A, Sekharam M, Cilenti L, Siddiquee
K, Khaled A, Zervos AS, Carter B, Turkson J and Jove R: Resveratrol
inhibits Src and Stat3 signaling and induces the apoptosis of
malignant cells containing activated Stat3 protein. Mol Cancer
Ther. 5:621–629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jung JE, Lee HG, Cho IH, Chung DH, Yoon
SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK, et al: STAT3 is a
potential modulator of HIF-1-mediated VEGF expression in human
renal carcinoma cells. FASEB J. 19:1296–1298. 2005.PubMed/NCBI
|
|
43
|
Zhou Y, Rajabi H and Kufe D: Mucin 1
C-terminal subunit oncoprotein is a target for small-molecule
inhibitors. Mol Pharmacol. 79:886–893. 2011. View Article : Google Scholar : PubMed/NCBI
|
